2016
DOI: 10.1007/s10384-016-0469-6
|View full text |Cite
|
Sign up to set email alerts
|

Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm

Abstract: BTX-A is a treatment with a high potential to improve ocular surface disorders induced by BEB.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0
1

Year Published

2017
2017
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(10 citation statements)
references
References 27 publications
0
9
0
1
Order By: Relevance
“…Isshiki et al [19] found that there is significant improvement in both the Schirmer test and TBUT test results with reduction in high-order ocular aberrations in patients of blepharospasm treated with botulinum toxin. In addition to the previously mentioned tests, Park et al [20] added lower lid tear meniscus height measured by optical coherence tomography and dacryoscintigraphy using 99 m technetium pertechnetate with similar results, confirming the improvement of dry eye manifestations after BTA injection in blepharospasm patients.…”
Section: Discussionmentioning
confidence: 99%
“…Isshiki et al [19] found that there is significant improvement in both the Schirmer test and TBUT test results with reduction in high-order ocular aberrations in patients of blepharospasm treated with botulinum toxin. In addition to the previously mentioned tests, Park et al [20] added lower lid tear meniscus height measured by optical coherence tomography and dacryoscintigraphy using 99 m technetium pertechnetate with similar results, confirming the improvement of dry eye manifestations after BTA injection in blepharospasm patients.…”
Section: Discussionmentioning
confidence: 99%
“…This hypothesis was supported by Ho et al [31] who injected BoNT in patients with lateral canthal rhytides and showed significantly decreased tear film stability as assessed by TBUT at 1- and 3-months post-BoNT injection. However, in several studies, TBUT significantly increased following BoNT injection in patients with facial movement disorders [54,62,63,64,65]. Moreover, our previous data have shown a significant increase in LLT from baseline at 1-month post-treatment (89.9 ± 16.7 [one month] vs. 75.1 ± 21.2 [baseline], P = 0.01) [39].…”
Section: Bont Effects On Tear Film Stability and Meibomian Gland Cmentioning
confidence: 95%
“…Авторы отмечают, что регулярные инъекции ботулинического токсина А устраняли как сами спазмы века, так и субъективные негативные ощущения. Однако перед проведением данной процедуры необходимо тщательно дифференцировать первичный блефароспазм, синдром сухого глаза, конъюнктивит, кератит и миастению [35][36][37][38].…”
Section: ботулотоксин в терапии и эстетической медицинеunclassified